[ET Net News Agency, 10 April 2018] Luye Pharma (02186) said the Group's chemical new
drug, Rotigotine Extended Release Microspheres for injection (LY03003), has obtained the
approval from the China Food and Drug Administration (CFDA) to proceed to Phase III
clinical trials in China.
This would significantly accelerate the research and development process of LY03003, and
shorten the time-to-market of the product.
LY03003 delivers medication by weekly intramuscular injections. It is the first product
worldwide to produce long-term Continuous Dopamine Stimulation. The stable release of the
drug in the human body can reduce the "on-off" phenomenon common in drug treatments for
patients with Parkinson's disease, and significantly improves motor complications common
among patients with late-stage Parkinson's disease. (HL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
2.570 -0.050 (-1.908%) Others
10/04/2018 12:28
Luye Pharma new drug approved for Phase III clinical trials
| Remark: | Real time quote last updated: 19/04/2024 12:06 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |